Elinzanetant - Bayer
Alternative Names: BAY-3427080; GSK 1144814A; GSK-1144814; NT 814Latest Information Update: 11 Oct 2024
At a glance
- Originator GlaxoSmithKline
- Developer Bayer; GlaxoSmithKline; NeRRe Therapeutics
- Class 2 ring heterocyclic compounds; Alcohols; Amides; Antipsychotics; Drug withdrawal therapies; Fluorinated hydrocarbons; Fluorobenzenes; Oxazines; Piperazines; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Vasomotor symptoms
- Phase II Sleep disorders
- Discontinued Opioid-related disorders; Schizophrenia
Most Recent Events
- 09 Oct 2024 US FDA accepts NDA for Elinzanetant for Vasomotor symptoms for review
- 28 Sep 2024 No recent reports of development identified for phase-I development in Vasomotor-symptoms(In volunteers) in Japan (PO, Capsule)
- 12 Sep 2024 Efficacy and adverse events data from phase-III OASIS-3 trial in Vasomotor symptoms released by Bayer